OpenEvidence, an AI platform built for doctors, has raised $250 million in a Series D funding round, pushing its valuation to $12 billion. The latest round was co-led by Thrive Capital and DST Global, showing strong investor confidence in tools that support clinicians with faster access to medical evidence.
OpenEvidence’s Series D comes after a fast run of major fundraising rounds over the past year. The company raised a $210 million Series B before closing a Series C in October 2025, when it was valued at about $6 billion.
The company has raised about $700 million in total in under a year, reflecting how quickly its reach has expanded across U.S. healthcare settings.
“If a doctor tried to stay current by reading only the new evidence in the top 10 medical journals and only the most recent changes to their specialty guidelines, it would take nine hours of their day, each day,” CEO Daniel Nadler said in a company release.
“Without a technology like OpenEvidence, doctors may miss critical new findings or guidelines simply because they lack the time to find them.”
OpenEvidence has seen sharp growth in real-world clinical use. In December 2025, the platform supported around 18 million clinical consultations by verified U.S. physicians. That figure marked a major jump from roughly 3 million monthly consultations a year earlier.
The company says more than 40% of U.S. physicians use OpenEvidence daily, and doctors access the tool across over 10,000 hospitals and medical centers. OpenEvidence also reported that 100 million Americans were treated last year by physicians using its platform during care.
OpenEvidence positions itself as a medical AI assistant that helps doctors search and interpret trusted clinical information quickly. Instead of pulling from broad internet sources, the platform focuses on evidence-based medical content, helping clinicians find relevant research and guidance when making decisions.
The company offers its service free to verified doctors and runs it using an advertising-supported business model. OpenEvidence also reported reaching more than $100 million in annual revenue, highlighting how fast the product has moved from adoption to monetization.
To strengthen trust and accuracy, OpenEvidence has built content partnerships with major medical organizations and publishers. These include the American Medical Association, The New England Journal of Medicine, JAMA and its specialty journals, the American Academy of Family Physicians, and the American College of Emergency Physicians.
(Rh/ARC)